Dopamine agonists and dopamine reuptake inhibitors provide similar quality of life for Parkinson disease patients
French parents sue after daughter mistakenly gets Moderna jab
29 December 2021Oxytocin in a developing fish brain determines later social behavior
29 December 2021Dopamine agonists and dopamine reuptake inhibitors provide similar quality of life for Parkinson disease patients
For patients with Parkinson disease on levodopa therapy, patient-rated quality of life is similar for those receiving adjuvant therapy with dopamine agonists compared with dopamine reuptake inhibitors (DRIs); and among DRIs, monoamine oxidase type B (MAO-B) inhibitors are preferable to catechol-O-methyltransferase (COMT) inhibitors, according to a study published online Dec. 28 in JAMA Neurology.
